Chronic Kidney Disease News

PHILADELPHIA — Although rare, hypercalcemia should be treated as a potential threat for patients with from severe tophaceous gout, according to a case study presented at the ASN Kidney Week.

The FDA has approved DefenCath, a catheter lock solution of taurolidine and heparin by CorMedix Inc., for adults with kidney failure on chronic hemodialysis, according to a press release.

PHILADELPHIA — Compared with controls, patients with chronic kidney disease showed greater accumulation of intermuscular adipose tissue that has a strong association with insulin resistance, according to data presented at ASN Kidney Week.

PHILADELPHIA — Pegloticase and methotrexate can be used to reduce blood pressure in patients with gout, hinting at a link between serum uric acid level and hypertension, according to data presented at the ASN Kidney Week conference.

SAN DIEGO — Patients with lupus who received sodium-glucose cotransporter-2 inhibitors demonstrated reduced risks for major adverse cardiovascular events and kidney disease, a speaker said at ACR Convergence 2023.

  Healio spoke with Daniel Coyne, MD, professor of medicine in the nephrology division at Washington University School of Medicine, about the challenges of managing hyperphosphatemia, new treatments and therapies, unmet needs in hyperphosphatemia management and more.

  Healio spoke with Daniel Coyne, MD, professor of medicine in the nephrology division at Washington University School of Medicine, about the challenges of managing hyperphosphatemia, new treatments and therapies, unmet needs in hyperphosphatemia management and more.

  Healio spoke with Daniel Coyne, MD, professor of medicine in the nephrology division at Washington University School of Medicine, about the challenges of managing hyperphosphatemia, new treatments and therapies, unmet needs in hyperphosphatemia management and more.

  Healio spoke with Daniel Coyne, MD, professor of medicine in the nephrology division at Washington University School of Medicine, about the challenges of managing hyperphosphatemia, new treatments and therapies, unmet needs in hyperphosphatemia management and more.

SAN DIEGO — Obinutuzumab use increases the chances of achieving complete renal response and lowers the risk for kidney-related events and time to flare in lupus nephritis, according to data presented at ACR Convergence 2023.